Confusion Over Sound-Alike Drugs: Monsanto's Celebrex Education Campaign

Monsanto Co.'s newest arthritis pill, Celebrex, has been causing concern among health-care professionals due to its similarity in name to other medications, including Celexa and Cerebyx. In response, the company is launching an education and advertising campaign aimed at mitigating the issue. The Food and Drug Administration (FDA) has received 70 reports of Celebrex being confused with other drugs, although no deaths or injuries have been reported.

Key Takeaways:

• The FDA has received 70 reports of Celebrex being confused with other drugs, with 13 people taking the wrong medication and 28 receiving incorrect prescriptions or purchasing the wrong medication.
• Pharmacy experts estimate that official reports drastically undercount the number of errors, suggesting that the actual number of mix-ups is significantly higher.
• The FDA has been cooperative with Monsanto, allowing the company to launch the education campaign, but has not ruled out the possibility of a trademark change to mitigate the issue.
• The education campaign, run by G.D. Searle & Co. and marketing partner Pfizer Inc., is expected to incur additional marketing costs.
• Celebrex and Vioxx, a rival drug, have both been approved for osteoarthritis and acute pain, but differ in their mechanism of action.

Statistics:

• 70 reports of Celebrex being confused with other drugs have been received by the FDA.
• 13 people have taken the wrong medication.
• 28 people received incorrect prescriptions or purchased the wrong medication.
• The potential marketing costs for the education campaign are unknown.

Sources:

• "Monsanto to Launch Education Campaign to Clear Up Celebrex Mix-Ups" (The Wall Street Journal, date unavailable)
• "FDA Clears Celebrex" (The Wall Street Journal, date unavailable)
• "Maison, Smith: New Hopes, New Fears" (PhRMA, date unavailable)